#Spain #Barcelona #Advanced Therapies #Phacilitate

Advanced Therapies Europe 2025: A New Era in Biotechnology

The eagerly anticipated Advanced Therapies Europe 2025 will be held in the vibrant city of Barcelona for the first time, marking a significant milestone in the field of biotechnology. Scheduled from September 2 to September 4, 2025, this year’s event promises a redesigned, high-impact format aimed at fostering meaningful connections among participants. With a strict limit of 500 attendees, the event emphasizes quality over quantity, enabling attendees to engage deeply in discussions that could shape the future of cell and gene therapies.

The venue, Hotel Arts, Ritz-Carlton, is located in one of Europe’s fastest-growing biotech hubs, providing a perfect backdrop for decision-makers from the biotech and pharmaceutical sectors, including investors, regulatory bodies, scientists, solution providers, and leading manufacturers. Over three days, participants can look forward to a range of stimulating content, strategic networking opportunities, and targeted business engagements.

A Focus on Cutting-Edge Issues

This year, the conference will tackle the most pressing issues facing the industry. Topics include investment strategies, market trends, manufacturing and scale-up strategies, clinical development and commercialization, new technologies, and the evolving global regulatory landscape. The format includes in-depth workshops, interactive sessions, and roundtable discussions designed to facilitate open dialogue and collaborative problem-solving.

The program will feature prominent speakers, such as Miguel Forte, CEO of Kiji Therapeutics, and Thomas Carlsen, CEO of Novo Nordisk Cellerator. Additionally, Ase Rosenqvist from Johnson & Johnson’s Nordic Cell Therapy Business Unit and Eleuterio Lombardo, Director of Cell Therapy Characterization at Takeda, will lend their insights, along with Angela Vollstedt, Director of the Global FE Portfolio for Cell and Gene Therapies at Novartis.

Two significant summits will also take place during the event: the Women in Advanced Therapies Congress and the Investment Summit. Both will emphasize mentoring, innovation, and strategic alignment, further enhancing the event’s focus on collaboration and future growth.

Focused on Innovation and Connection

Ingerid Sorgaard, Head of Content at Phacilitate, shared insights on the redesign of this year’s event. “We reimagined this year’s event to be more dynamic, interactive, and connection-oriented. It’s not just about sharing information; it’s about engaging in the right conversations in the right environment. From curated roundtable discussions and immersive workshops to rooftop networking opportunities and interactive formats, every element is designed to cultivate meaningful connections, generate new insights, and drive genuine collaboration.”

Given the limited availability of spots, early registration is highly encouraged. Potential attendees can sign up now at Advanced Therapies Europe to secure their participation. The early bird pricing runs until April 18, providing an added incentive to confirm attendance sooner rather than later.

As the field of advanced therapies continues to evolve, so too does the necessity for networking platforms that foster collaboration, innovation, and strategic investment. Advanced Therapies Europe 2025 is poised to be an influential gathering that not only highlights the latest advancements in biotechnology but also sets the groundwork for future developments in cell and gene therapy.

For inquiries, please contact Abby Cairns, Senior Marketing Manager at Phacilitate, via email at [email protected]